Drug Discovery Technologies

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Bioanalytical Instruments
• Nuclear Magnetic Resonance
• Mass Spectroscopy
• Microplate Readers
• Chemotherapy Instruments
• High Throughput Screening (HTS)
• Genomics
• Proteomics
• Bioinformatics
• Biochip
• Pharmacogenomics
• Other Drug Discovery Technologies

II. EXECUTIVE SUMMARY

1. Industry Overview

• Drug Discovery Outsourcing - A Necessity
• Current & Future Analysis
• Analysis by Geographic Region
• Analysis by Technology Type

2. An Overview of Key Emerging Technologies

• Bioinformatics
• Pharmacogenomics
• Theragnostics
• Targeted Therapy
• Mass Spectrometry - A New Catalyst for Technological Developments

3. Market Trends

• New Technologies Fire Up Drug Discovery Market
• Obesity Related Diseases Driving Drug Discovery Research
• Biochips Change Face of Drug Discovery
• Genomics and Proteomics Gaining Prominence
• Genomics Drives Bioinformatics Growth in Drug Discovery
• Market Scenario of Human Genome Sciences (HGS)
• International Initiatives Expand Proteomics

4. Drug Discovery - An Overview

• Drug Discovery - Definition
• Drug Discovery Process
• Drug Discovery Technologies
• Bioanalytical Instruments
• Nuclear Magnetic Resonance
• Mass Spectroscopy
• Microplate Readers
• Chemotherapy Instruments
• High Throughput Screening
• Genomics
• Functional Genomics
• Structural Genomics
• Proteomics
• Classification of Proteomics
• Bioinformatics
• Categories of Bioinformatics
• Advantages of Bioinformatics in Drug Discovery
• Market Highlights
• Biochip
• Types of Biochips
• Pharmacogenomics
• A Revolutionary Health Care Therapy
• Other Drug Discovery Technologies
• Combinatorial Chemistry
• Lab-on-a-Chip
• RNA Interference

5. Product Launches

• Affymetrix Introduces Cytogenetic Solution
• Affymetrix Introduces DMET Early Access Solution
• Affymetrix Microarray Platform to feature in Pathwork' s Diagnostic Test
• Bio-Rad Laboratories Rolls Out Vasculitis Kit for BioPlex 2200 System
• PerkinElmer Develops Products for High-Throughput Screening
• Tecan to Introduce Multimode Microplate Reader- Infinite M1000
• Waters Introduces Next-Generation MS System - Synapt(tm)
• Tripos International Launches SYBYL(r)8.0
• Bio-Rad Laboratories Unveils In2it A1C Analyzer for Diabetic Patients
• Charles River Launches Endosafe(r)-MCS(tm) Endotoxin Detection System
• Invitrogen Launches Human Embryonic Stem Cells Monitoring Kit
• Sigma-Aldrich Introduces Proteomics Dynamic Range Standard
• Molecular Devices Develops Arcturus (XT) (tm) LMC Instrument
• Fujitsu' s BioSciences Renames CAChe Software and Releases Scigress Explorer(tm)
• Tripos International Unveils Topomer CoMFA(r)
• Tripos International Launches Topomer Search
• Sigma-Aldrich Introduces GenomePlex(r)
• Agilent Unveils Dual Mode Microarray Platform
• Molecular Devices Launches ImageXpressULTRA(tm)
• Applied Biosystems Commercializes TaqMan(r) Influenza
• Agilent Launches Assay Kits for Lab-On-a-Chip Platform
• Affymetrix Unveils GeneChip(r) Microarrays
• Quantum Introduces Drug Discovery Software
• Invitrogen Launches Stealth(tm) RNAi Human Kinase Collection
• PerkinElmer Unveils BioXPRESSION(tm)
• Affymetrix and ParAllele Jointly Introduce MegAllele(tm) Assays
• Agilent Launches HD-CGH Custom Microarrays
• Applied Biosystems and MDS Sciex Unveil Tempo(tm) LC
• Beckman Coulter Presents Chemistry Analyzer for Clinical Testing
• Molecular Devices Launches ADME Assay Kits
• Applied Biosystems Unveils LS*LIMS(tm) Software
• Affymetrix Presents NimbleExpress(tm)
• Agilent Releases Software for Pharma QC/QA

6. Recent Industry Activity

• Affymetrix Acquires USB Corp
• Roche Acquires Ventana Medical Systems
• Bruker BioSciences Acquires Bruker BioSpin Group
• Takeda Signs Agreement to Take Over Millennium
• Pfizer to Acquire Serenex
• Implant Sciences to Acquire Ion Metrics
• NascaCell and Archemix Expand Partnership for Aptamer-Based Drugs
• DiscoveRx and Cosmo Bio Sign Distribution Agreement
• Zydus Cadila Enters into Collaboration with Prolong Pharmaceuticals
• PsychoGenics Enters into Drug Discovery Agreement with Dainippon
• Zydus Cadila Collaborates with Karo Bio
• Nicholas Piramal' s R&D Unit Extends Alliance with Eli Lilly
• Dr. Reddy' s Signs Collaboration Agreement with 7TM Pharma
• Synamatix Enters into Collaboration with Universiti Malaysia
• Monogram Enters into Exclusive Collaboration Agreement with Avexa
• Caliper Life Sciences Collaborates with Horizon Discovery
• Galapagos Signs Collaborative Agreement with Allergan for Drug Discovery
• Sigma-Aldrich Inks Exclusive Distribution Partnership with Atlas Antibodies
• PsychoGenics Enters into New Agreement with Eli Lilly
• Ambrx and Eli Lilly Enter into Alliance for Drug Discovery
• BioSeek Enters into Agreement with Dainippon Sumitomo
• NicOx Extends Collaboration with Pfizer
• BioFocus DPI Extends Contract with Lilly
• Invitrogen to Collaborate with Tecan
• Ranbaxy Forms New Drug Discovery Company
• Protagen to Expand Protein Biochips Business
• Znomics Expands Facilities for Drug Discovery
• Eli Lilly Acquires ICOS Corporation
• CMC Announces Acquisition of ICOS Biologics Facility from Eli Lilly
• SurModics Acquires Brookwood
• Commonwealth Biotechnologies Acquires Tripos Discovery Research
• VASTox Acquires Dextra Laboratories and Daniolabs
• Takeda Completes Acquisition of Paradigm
• Wyeth Completes the Acquisition of Haptogen
• Roche Takes Over Nimblegen
• AMRI Acquires Pharmaceutical Manufacturing Units in India
• Morvus Acquires Cardiff Biologicals and ProTides
• Agilent Technologies Acquires Stratagene
• AstraZeneca Takes Over MedImmune
• Ocimum Acquires Gene Logic' s Genomics Business
• Newsham Genetics Acquires Monsanto Choice Genetics
• Evotec Takes Over Combinature Biopharm' s Drug Discovery Unit
• BioServe Takes Over Genomics Collaborative
• Thomson Takes Over Unleashed Informatics Ltd
• Thomson Completes Acquisition of Prous Science
• MDS Acquires Molecular Devices
• Evotec to Take over Renovis
• Ecopia Merges with Caprion
• Domainex Merges with NCE Discovery
• Thallion Sells Majority Interest in Caprion Proteomics Business
• Affymetrix Enters into Licensing Agreement with Empire Genomics
• Graffinity Pharmaceuticals Signs Drug Discovery Agreement with Amgen
• ArQule Signs License Deal with Kyowa Hakko
• Toshiba, Canon and Others to Join Forces to Develop Biochips
• Orion and ChemDiv Enter into Collaborative Deal
• Graffinity Enters into Drug Discovery Collaboration with Pfizer
• Tata Enterprise Establishes Pharmaceutical Development Centre
• Nicholas Piramal Collaborates with Merck
• Eksigent Signs Distribution Agreement with Interface Engineering
• LEAD Therapeutics Enters Collaboration with Shang Pharma
• MDS Pharma Expands Chinese Lab Operations
• Ambit Extends Drug Discovery Collaboration with Bristol - Myers Squibb
• PsychoGenics Enters into Agreement with Cephalon for Drug Discovery
• Abbott and Caprion Proteomics Extends Partnership
• Agilent Technologies and BioNanomatrix Enters into Collaboration
• Evotec Extends Partnership with Boehringer Ingelheim
• Evotec and Interprotein Enter into Collaboration
• Galapagos Forms Drug Innovation Alliance with AstraZeneca
• Proteome Systems and BD Enter into an Agreement
• Galapagos Extends Drug Innovation Partnership with Amgen
• Dimerix Collaborates with NCDS
• ACE BioSciences and CLC Bio Enter into Collaborative Agreement
• Ambrx Enters into Strategic Agreement with Merck & Co
• Galapagos and Cystic Fibrosis Collaborate for Drug Discovery
• BioDiscovery Collaborates with Illumina
• Advinus Collaborates with DNDi
• Jubilant & Forest Enter into Partnership Deal
• Cisbio to Employ Lumi4(tm) Technology of Lumiphore
• Invitrogen Corporation Signs Agreement with Emiliem to Screen Kinase Inhibitors
• AMRI Establishes New Center in India
• Actavis Takes Over Abrika
• Galapagos Announces Acquisition of Inpharmatica
• PerkinElmer Acquires Proteomics Technology from Agilix
• BD Finishes Acquisition of GeneOhm
• Albany Acquires ComGenex in Hungary
• Agilent Acquires Yokogawa
• Strand Forms Partnership with Microsoft BioIT Alliance
• Nicholas Piramal Signs License Agreement with Morvus Technology
• Cellomics and Evotec Sign a Patent License Agreement
• PerkinElmer Opens New Technology Center in Shanghai
• Affymetrix Acquires ParAllele
• Agilent Acquires Computational Biology
• MultiCell and Living Cell Enter into a Joint Venture
• Fujitsu and Ensemble Enter into Licensing Agreement
• Structural GenomiX Modifies Licensing Agreement with Lilly
• Provid Enters into Research Services Agreement with Palatin
• NascaCell Signs Co-marketing Agreement with DPI
• Evotec and P&G Sign Supply Agreement
• Invitrogen Signs Collaborative Agreement with NCDS
• HistoRx Enters into Collaboration with Eli Lilly
• Invitrogen and Applied Biosystems Forge Strategic Alliance
• UCB and ChemBridge Form Collaboration in Discovery Chemistry
• Pharmacopeia and CV Therapeutics Form Drug Discovery and Development Collaboration
• OriGene Enters into Collaboration with Cytomyx
• Discovery Partners Divests Discovery Systems Business to Nexus
• CRL Acquires River Valley Farms
• Agilent Acquires Silicon
• Medarex Acquires Ability Biomedical
• National Instruments Enters into Joint Venture Agreement with Agilent
• Amersham Enters into 3-Year Distribution Agreement with Guava
• ChemBridge Signs an Agreement with Merck & Co.
• Bristol-Myers Collaborates with MEDX
• Bayer Enters into Partnership with Physiomics
• Pharmacopeia Spins-Off Pharmacopeia Drug Discovery
• Abbott Enters into Collaboration with Caprion
• Vertex Divests Instrumentation Assets to Aurora

7. Focus on Select Global Players

• Abbott Laboratories (US)
• Affymetrix Inc. (US)
• Agilent Technologies Inc. (US)
• Albany Molecular Research, Inc. (US)
• Amersham Biosciences (US)
• Applera Corporation (US)
• ArQule Inc. (US)
• AstraZeneca (UK)
• BD Biosciences (US)
• Bio-Rad Laboratories, Inc. (US)
• BioSciences Group (Japan)
• Caliper Life Sciences, Inc. (US)
• Capital GenomiX (US)
• Caprion Proteomics (Canada)
• Charles River Laboratories International, Inc. (US)
• ChemBridge Corporation (US)
• deCODE Genetics, Inc (Iceland)
• Evotec AG (Germany)
• Galapagos NV (Belgium)
• Incyte Corporation (Formerly Incyte Genomics Inc.) (US)
• Infinity Pharmaceuticals, Inc. (US)
• Invitrogen Corporation (US)
• Medarex, Inc. (US)
• Merck & Co., Inc. (US)
• Millennium Pharmaceuticals, Inc. (US)
• National Center for Drug Screening (China)
• PerkinElmer, Inc. (US)
• Pharmacopeia Inc. (US)
• Proteome Systems (Australia)
• Quantum Pharmaceuticals (Russia)
• Shimadzu Corporation (Japan)
• Sigma-Aldrich (US)
• Tecan Group (Switzerland)
• Thallion Pharmaceuticals, Inc. (Canada)
• Tripos International (US)

8. Global Market Perspective

• Table 1: World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 2: World Long-term Projections for Drug Discovery Technologies by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 3: World 10-Year Perspective for Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Analytics by Drug Discovery Technology Type
• Table 4: World Recent Past, Current & Future Analysis for Bioanalytical Instruments by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 5: World Long-term Projections for Bioanalytical Instruments by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 6: World 10-Year Perspective for Bioanalytical Instruments by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 7: World Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 8: World Long-term Projections for High Throughput Screening (HTS) by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 9: World 10-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 10: World Recent Past, Current & Future Analysis for Biochip by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 11: World Long-term Projections for Biochip by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 12: World 10-Year Perspective for Biochip by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 13: World Recent Past, Current & Future Analysis for Proteomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 14: World Long-term Projections for Proteomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 15: World 10-Year Perspective for Proteomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 16: World Recent Past, Current & Future Analysis for Genomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 17: World Long-term Projections for Genomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 18: World 10-Year Perspective for Genomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 19: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 20: World Long-term Projections for Bioinformatics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 21: World 10-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 22: World Recent Past, Current & Future Analysis for Pharmacogenomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 23: World Long-term Projections for Pharmacogenomics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 24: World 10-Year Perspective for Pharmacogenomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 25: World Recent Past, Current & Future Analysis for Other Drug Discovery Technologies by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 26: World Long-term Projections for Other Drug Discovery Technologies by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 27: World 10-Year Perspective for Other Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Overview
  • US Leads the World High Throughput Screening (HTS) Market
  • Current & Future Analysis
  • Product Launches
  • Strategic Corporate Developments
  • Focus on Select US Players
  • Abbott Laboratories
  • Affymetrix Inc.
  • Agilent Technologies Inc.
  • Albany Molecular Research, Inc.
  • Amersham Biosciences
  • Applera Corporation
  • ArQule Inc.
  • BD Biosciences
  • Bio-Rad Laboratories, Inc.
  • Caliper Life Sciences, Inc.
  • Capital GenomiX
  • Charles River Laboratories International, Inc.
  • ChemBridge Corporation
  • deCODE Genetics, Inc.
  • HistoRx, Inc.
  • Incyte Corporation (Formerly Incyte Genomics Inc.)
  • Infinity Pharmaceuticals, Inc.
  • Invitrogen Corporation
  • Medarex, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • PerkinElmer, Inc.
  • Pharmacopeia Inc..
  • Provid Pharmaceuticals, Inc.
  • Tigris Pharmaceuticals, Inc.
  • Sigma-Aldrich
  • Tripos International.
• B. Market Analytics
  • Table 28: US Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 29: US Long-term Projections for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 30: US 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

• A. Market Analysis
  • Current & Future Analysis
  • Strategic Corporate Developments
  • Focus on Select Canadian Players
  • Caprion Proteomics
  • Thallion Pharmaceuticals, Inc.
• B. Market Analytics
  • Table 31: Canadian Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 32: Canadian Long-term Projections for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 33: Canadian 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Current & Future Analysis
  • Japan Resembles US in Life Science Research
  • Strategic Corporate Developments
  • Focus on Select Japanese Players
  • BioSciences Group
  • Shimadzu Corporation
• B. Market Analytics
  • Table 34: Japanese Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 35: Japanese Long-term Projections for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 36: Japanese 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Current & Future Analysis
  • An Overview of Pharmacogenomics and Personalized Medicine
  • Emerging Trends in Proteomics Technology
  • Protein Classification
  • Protein Separation
  • Market Trends
  • European Market for Drug Discovery Tools
  • UK Government Supports Proteomics Research
  • Drug Discovery Outsourcing in Europe
  • Recent Industry Activity
  • Focus on Select European Players
  • AstraZeneca (UK)
  • deCODE Genetics, Inc (Iceland)
  • Evotec AG (Germany)
  • NascaCell IP GmbH (Germany)
  • Quantum Pharmaceuticals (Russia)
  • Tecan Group (Switzerland)
  • UCB (Belgium)
• B. Market Analytics
  • Table 37: European Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 38: European Long-term Projections for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 39: European 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Rest of World

• A. Market Analysis
  • Current & Future Analysis
  • Asia-Pacific
  • Emerging Opportunities
  • Cost Advantage in Asia Attracts Global Drug Discovery Industry
  • Regulations Affect Asia-Pacific Drug Discovery Market
  • India
  • Bioinformatics Market in India
  • Scope and Demand for Bioinformatics Market to Expand Significantly by 2010
  • Discovery of Therapeutic Molecules - A New Buzzword for Growth Acceleration
  • Strategic Corporate Developments
  • Focus on Select Players
  • National Center for Drug Screening (China)
  • Proteome Systems (Australia)
• B. Market Analytics
  • Table 40: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics & Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Table 41: Rest of World Long-term Projections for Drug Discovery Technologies by Technology Type - Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 42: Rest of World 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE